Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents.

abstract：PURPOSE:Chemosensitizers such as cyclosporin A can increase intracellular accumulation of chemotherapeutic agents such as Adriamycin in certain multidrug-resistant (MDR) cell lines with overexpression of P-glycoprotein. It is likely that, when combined with cyclosporin A, hyperthermia could increase membrane permeabili...

journal_title：Cancer chemotherapy and pharmacology

authors： Larrivée B,Averill DA

更新日期：2000-01-01 00:00:00

abstract：:Twenty patients with bladder cancer (T1, 3 patients; T2, 6 patients; T3, 8 patients; T4a, 3 patients) were preoperatively treated with intra-arterial doxorubicin chemotherapy in combination with low-dose irradiation. The originally scheduled operations were as follows: total cystectomy in 16 patients (T1 + cis, 1 pati...

journal_title：Cancer chemotherapy and pharmacology

authors： Uyama T,Moriwaki S,Yokozeki A,Kitada K,Higa I,Shiotsu T,Fujita J

更新日期：1987-01-01 00:00:00

abstract：:The novel isocoumarin 2-(8-hydroxy-6-methoxy-1-oxo-1 H-2-benzopyran-3-yl) propionic acid (NM-3) has completed phase I clinical evaluation as an orally bioavailable angiogenesis inhibitor. NM-3 directly kills both endothelial and tumor cells in vitro at low mM concentrations and is effective in the treatment of diverse...

journal_title：Cancer chemotherapy and pharmacology

authors： Agata N,Nogi H,Bamberg M,Milhollen M,Pu M,Weitman S,Kharbanda S,Kufe D

更新日期：2005-12-01 00:00:00

abstract：:We have developed and validated a selective analytical procedure, based on ion-exchange normal-phase liquid chromatography with fluorescence detection and liquid-liquid extraction, for the analysis of vinblastine (VBL) in biological matrices. The assay is suitable for the determination of the parent compound and its m...

journal_title：Cancer chemotherapy and pharmacology

authors： van Tellingen O,Beijnen JH,Nooijen WJ,Bult A

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:To compare the in vitro cytotoxicity of nedaplatin, an investigational platinum analog, with that of the standard platinum agents, cisplatin and carboplatin, against fresh human, epithelial ovarian cancers. METHODS:The Hamburger-Salmon human tumor colony-forming assay (HTCA) was used to measure the chemosensit...

journal_title：Cancer chemotherapy and pharmacology

authors： Alberts DS,Fanta PT,Running KL,Adair LP Jr,Garcia DJ,Liu-Stevens R,Salmon SE

更新日期：1997-01-01 00:00:00

abstract：:Using flow cytometry and conventional spectrofluorimetry we have previously shown that chloroethylnitrosoureas (CNUs) can exhibit marked inhibition of cellular enzymes catalysing hydrolysis of fluorescein diacetate (FDA). More potent inhibition was seen for the carbamoylating CNUs, whereas alkylating agents were large...

journal_title：Cancer chemotherapy and pharmacology

authors： Dive C,Workman P,Watson JV

更新日期：1989-01-01 00:00:00

abstract：:A total of 13 patients receiving bone marrow transplants (BMT) for treatment of different haematological diseases were investigated. Conditioning therapy preceding BMT consisted of fractionated total-body irradiation (12 Gy) and high-dose chemotherapy with cyclophosphamide (2 +/- 60 mg/kg). Patients stratified to be a...

journal_title：Cancer chemotherapy and pharmacology

authors： Ladner C,Ehninger G,Gey KF,Clemens MR

更新日期：1989-01-01 00:00:00

abstract：:The cytotoxicity of 5-fluorouracil (5-FU) is due in part to the incorporation of the base into RNA molecules. We assessed the cytotoxicity of 5-FU in human colonic carcinoma HT-29 cells and examined mRNA activity (measured by protein biosynthesis in vivo and in vitro) and the maturation of rRNA precursors as two possi...

journal_title：Cancer chemotherapy and pharmacology

authors： Greenhalgh DA,Parish JH

更新日期：1989-01-01 00:00:00

abstract：:A 62-year-old patient on long-term haemodialysis who developed an inoperable T2N3Mo squamous-cell carcinoma of the larynx was treated with weekly low-dose methotrexate (MTX) after failing to respond to radiotherapy. The patient was initially given one dose of 10 mg MTX (6 mg/m2) as a 1-h infusion, then he received thr...

journal_title：Cancer chemotherapy and pharmacology

authors： Thomson AH,Daly M,Knepil J,Harden P,Symonds P

更新日期：1996-01-01 00:00:00

abstract：:Of 54 patients with advanced breast cancer, 21/37 (57%) with oestrogen receptor-positive (ER+) tumours and 11/17 (65%) with oestrogen receptor-negative (ER-) tumours responded to cytotoxic chemotherapy. These data and a survey of the literature indicate that oestrogen receptor status is not a determinant of response t...

journal_title：Cancer chemotherapy and pharmacology

authors： Rubens RD,King RJ,Sexton S,Minton MJ,Hayward JL

更新日期：1980-01-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer death in the world. Recently, targeted therapy and anti-programmed cell death receptor 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) immunotherapy have made great progress in treatment of lung cancer. However, responses to these therapies are variable, influenced b...

journal_title：Cancer chemotherapy and pharmacology

authors： Huang C,Liu S,Tong X,Fan H

更新日期：2018-08-01 00:00:00

abstract：PURPOSE:Erlotinib (Tarceva®), a potent small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase, has been evaluated to treat infants and children with primary brain tumors. The pharmacokinetics of erlotinib and its primary metabolite OSI-420 were characterized and exposure-safety associations we...

journal_title：Cancer chemotherapy and pharmacology

authors： Reddick SJ,Campagne O,Huang J,Onar-Thomas A,Broniscer A,Gajjar A,Stewart CF

更新日期：2019-10-01 00:00:00

abstract：PURPOSE:This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients. METHODS:Five dose level combinations with irinotecan (from 180 to 240 mg/m(2), day 1, q21), capecitabine (1,...

journal_title：Cancer chemotherapy and pharmacology

authors： Bajetta E,Di Bartolomeo M,Buzzoni R,Ferrario E,Dotti KF,Mariani L,Bajetta R,Gevorgyan A,Venturino P,Galassi M

更新日期：2009-06-01 00:00:00

abstract：PURPOSE:Dinaciclib inhibits cyclin-dependent kinases 1, 2, 5, and 9 with a better therapeutic index than flavopiridol in preclinical studies. This study assessed the activity of dinaciclib in acute leukemia both in the clinic and in vitro. METHODS:Adults with relapsed/refractory acute myeloid leukemia (n = 14) and acu...

journal_title：Cancer chemotherapy and pharmacology

authors： Gojo I,Sadowska M,Walker A,Feldman EJ,Iyer SP,Baer MR,Sausville EA,Lapidus RG,Zhang D,Zhu Y,Jou YM,Poon J,Small K,Bannerji R

更新日期：2013-10-01 00:00:00

abstract：:The prediction of tumor resistance to antineoplastic drugs remains an important challenge in cancer chemotherapy. Several methods have been proposed in this connection, but they present a number of problems such as clinical relevance and applicability. In the present work we put forward an original methodology to asse...

journal_title：Cancer chemotherapy and pharmacology

authors： Pauwels O,Kiss R

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:To further improve the prognosis of esophageal cancer patients, it is necessary to investigate new treatment strategies. The purposes of this study were to retrospectively assess the safety and efficacy of neoadjuvant chemoradiotherapy (CRT) with docetaxel/cisplatin/5-fluorouracil (DCF) (DCF-RT) in patients wit...

journal_title：Cancer chemotherapy and pharmacology

authors： Sasaki K,Uchikado Y,Omoto I,Arigami T,Osako Y,Noda M,Okumura H,Maemura K,Higashi R,Yoshiura T,Natsugoe S

更新日期：2019-03-01 00:00:00

abstract：PURPOSE:The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. METHODS:Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.0 µCi) under fasting conditions. Blood, plasma, urine, and fecal samples wer...

journal_title：Cancer chemotherapy and pharmacology

authors： Zollinger M,Lozac'h F,Hurh E,Emotte C,Bauly H,Swart P

更新日期：2014-07-01 00:00:00

abstract：:Cisplatin-induced emesis is one of the most feared side effects in cancer treatment. High-dose metoclopramide may prevent only 30-40% of cases of acute emesis. Investigations to test the efficacy of new antiemetics are mandatory. We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hyd...

journal_title：Cancer chemotherapy and pharmacology

authors： Chang TC,Hsieh F,Lai CH,Tseng CJ,Cheng HH,Li CL,Michael BJ,Soong YK

更新日期：1996-01-01 00:00:00

abstract：:This report describes the physicochemical and pharmacokinetic parameters of seven chlorambucil esters, which were compared with those of chlorambucil. These esters were designed as chlorambucil prodrugs to increase the brain penetration and concentration vs time profile of chlorambucil within the CNS for potential tre...

journal_title：Cancer chemotherapy and pharmacology

authors： Greig NH,Genka S,Daly EM,Sweeney DJ,Rapoport SI

更新日期：1990-01-01 00:00:00

abstract：BACKGROUND:No specific treatment guidelines are available for triple-negative breast cancers, defined by a lack of expression of estrogen (ER), progesterone (PgR), and HER2 receptors. PATIENTS AND METHODS:We investigated in patients with T2-T3 N0-3 ER, PgR <10% and HER2 negative breast cancers the activity both in ter...

journal_title：Cancer chemotherapy and pharmacology

authors： Torrisi R,Balduzzi A,Ghisini R,Rocca A,Bottiglieri L,Giovanardi F,Veronesi P,Luini A,Orlando L,Viale G,Goldhirsch A,Colleoni M

更新日期：2008-09-01 00:00:00

abstract：:To evaluate the value of beta-2-microglobulin as an indicator of acute and long-term cis-platinum-induced nephrotoxicity, 51Cr-EDTA clearance and serum concentration and urinary excretion of beta-2-microglobulin were measured in 18 patients treated with a regimen including cis-platinum. Before treatment all values wer...

journal_title：Cancer chemotherapy and pharmacology

authors： Sørensen PG,Nissen MH,Groth S,Rørth M

更新日期：1985-01-01 00:00:00

abstract：:The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer. In all, 60 metastatic colorectal cancer patients with measurable disease...

journal_title：Cancer chemotherapy and pharmacology

authors： Kato T,Mishima H,Ikenaga M,Murata K,Ishida H,Fukunaga M,Ota H,Tominaga S,Ohnishi T,Amano M,Ikeda K,Ikeda M,Sekimoto M,Sakamoto J,Monden M

更新日期：2008-02-01 00:00:00

abstract：PURPOSE:The aromatase inhibitor, letrozole, is being investigated in experimental animal models as a novel treatment for high-grade gliomas (HGGs). To facilitate optimal dosing for such studies, we evaluated the plasma and brain pharmacokinetics (PK) of letrozole in NOD-scid gamma (NSG) mice, which are frequently emplo...

journal_title：Cancer chemotherapy and pharmacology

authors： Arora P,Adams CH,Gudelsky G,DasGupta B,Desai PB

更新日期：2019-01-01 00:00:00

abstract：:There is no argument over using epidermal growth factor receptor (EGFR) mutation status to guide the frontline treatment for advanced lung adenocarcinoma (LADC); however, the role of the testing in lung squamous cell carcinoma (LSQC) remains controversial. Currently, the guidelines/consensus statements regarding EGFR ...

journal_title：Cancer chemotherapy and pharmacology

authors： Chiu CH,Chou TY,Chiang CL,Tsai CM

更新日期：2014-10-01 00:00:00

abstract：PURPOSE:Cancer, a major public health problem, exhibits significant redox alteration. Thioredoxin (Trx) system, including Trx and Trx reductase (TrxR), as well as Trx-interacting protein (TXNIP) play important roles in controlling the cellular redox balance in cancer cells. In most cancers, Trx and TrxR are usually ove...

journal_title：Cancer chemotherapy and pharmacology

authors： Jia JJ,Geng WS,Wang ZQ,Chen L,Zeng XS

更新日期：2019-09-01 00:00:00

abstract：PURPOSE:This study was conducted to define the activity of irofulven in the treatment of a series of xenografts derived from human glioblastoma multiforme growing subcutaneously and intracranially in athymic nude mice. METHODS:Athymic mice bearing subcutaneous or intracranial tumors were treated with irofulven at a 10...

journal_title：Cancer chemotherapy and pharmacology

authors： Friedman HS,Keir ST,Houghton PJ,Lawless AA,Bigner DD,Waters SJ

更新日期：2001-11-01 00:00:00

abstract：:Carmustine (BCNU) has proved to be of value against a variety of primary brain tumors. This agent exhibits a steep dose-response curve in in vitro and animal tumor models and has been proposed for use in high-dose chemotherapy as a single agent or in combination. We conducted a phase II study to assess high-dose BCNU ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bouffet E,Khelfaoui F,Philip I,Biron P,Brunat-Mentigny M,Philip T

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:Long-term hormonal ablation in prostate cancer is associated with decreased overall health and quality of life. Few reports emphasized the role of chemotherapy in the management of early stage prostate cancer. This study analyzed the safety and efficacy of androgen deprivation therapy (ADT) plus chemotherapy as...

journal_title：Cancer chemotherapy and pharmacology

authors： Amato R,Stepankiw M,Gonzales P

更新日期：2013-06-01 00:00:00

abstract：:Severe, debilitating nausea and vomiting are seen in almost 100% of patients treated with cis-platinum. These side-effects can be so severe and prolonged as to preclude therapy in a large number of patients. Commonly used antiemetics have had only limited success in controlling cis-platinum-induced nausea and vomiting...

journal_title：Cancer chemotherapy and pharmacology

authors： Aapro MS,Alberts DS

更新日期：1981-01-01 00:00:00

abstract：PURPOSE:Brivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development for the treatment of hepatocellular and colon carcinomas. In vitro and in vivo studies were conducted to characterize the preclinical pharmacokinetics and disposition of brivanib and brivani...

journal_title：Cancer chemotherapy and pharmacology

authors： Marathe PH,Kamath AV,Zhang Y,D'Arienzo C,Bhide R,Fargnoli J

更新日期：2009-12-01 00:00:00